Investor Contact:
investors@genomichealth.com

Corporate Fact Sheet

Key Facts

(as of 9.30.16)

Employees: **>830**

NASDAQ Ticker: **GHDX**

Q316 Revenue: **$82.3M**, 12% year-over-year increase

Cash and Cash Equivalents & Short-term Marketable Securities (exclusive of a corporate equity investment): **$83.6M**

Shares Used in Computing Basic Net Loss Per Share (3 months): **33.4M**

Management

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer & President

G. Bradley Cole,
Chief Operating Officer &
Chief Financial Officer

Steven Shak, M.D.,
Co-Founder, Chief Scientific Officer

Frederic Pla, Ph.D.,
Chief Business & Product Development Officer

Jim Vaughn, R.Ph.,
Chief Commercial Officer

Phil Febbo, M.D.,
Chief Medical Officer

Laura Leber,
Chief Communications Officer

Kim McEachron,
Chief People Officer

Jason W. Radford,
Chief Legal Officer & Secretary

Mike Vedda
Chief Information Officer

Joffre Baker, Ph.D.,
Co-Founder, Senior Biology Fellow

Ellen Beasley, Ph.D.,
Senior Vice President,
Products and Services R&D

Jon Cassel, Ph.D.,
Senior Vice President, Operations

Genomic Health, Inc. is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. With it's Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX® gene expression tests for breast, prostate and colon cancer that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests with the recently launched Oncotype SEQ® Liquid Select and collaboration with Epic Sciences to commercialize its AR-V7 test in 2017. The company is based in Redwood City, California with international headquarters in Geneva, Switzerland.

- For more information, please visit www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

Business Model

Genomic Health's business model is based on the belief that clinically validated standardized genomic tests, like our Oncotype IQ portfolio of tests, provide valuable information for patients, physicians and payors.

- We fund our own internal research and development, and forge clinical study collaborations with leading independent groups to validate our findings. We now have prospective evidence from more than 63,000 patients demonstrating that the Oncotype DX Breast Recurrence Score™ accurately predicts outcomes, including initial results from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx sponsored by the National Cancer Institute and recently published by *The New England Journal of Medicine*.
- We make significant investments in R&D to expand our advanced genomic discovery program and support the development of novel tests to aid in personalized treatment decisions for patients with cancer.
- Our tests are commercially available through our clinical reference laboratory located in Redwood City, California, which is accredited under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and by the College of American Pathologists, or CAP. In addition, this laboratory is an ISO 15189:2012 Internationally-Recognized Accredited Laboratory for Clinical Testing.
- Our commercial organization sells directly to the physician community, providing detailed information and streamlined ordering for doctors.
- We remain focused on ensuring access for healthcare providers and patients who can benefit from molecular information.
- Access to our tests enables personalized treatment decision-making and can result in cost savings to the individual and the healthcare system.

Investor Contact:
investors@genomichealth.com

Board of Directors

Julian Baker,
Managing Partner,
Lead Independent Director,
Baker Brothers Investments

Felix Baker, Ph.D.,
Managing Partner,
Baker Brothers Investments

Fred Cohen, M.D., D.Phil.,
Partner, TPG

Henry J. Fuchs, M.D.,
Executive Vice President &
Chief Medical Officer,
BioMarin Pharmaceutical Inc.

Ginger L. Graham,
President & Chief Executive Officer, Two Trees Consulting; Former President & Chief Executive Officer, Amylin Pharmaceuticals

Randall Livingston,
Vice President for Business Affairs & Chief Financial Officer, Stanford University

Geoffrey M. Parker,
Member of the Board of Directors at ChemoCentryx, Inc. & Sunesis Pharmaceuticals, Inc.

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer &
President, Genomic Health, Inc.

Third Quarter 2016 Highlights

Oncotype DX Commercial Progress

- As of September 30, 2016, the company's flagship line of Oncotype DX gene expression tests has been used to guide treatment decisions for more than 700,000 cancer patients worldwide.
- Established an additional coverage for the Oncotype DX Genomic Prostate Score™, bringing the total number of prostate cancer covered U.S. lives to more than 61 million.

Pipeline, Presentations and Publications

- Announced positive topline results from a prostate cancer clinical validation study demonstrating Oncotype DX is a strong predictor of the development of metastasis and prostate cancer death in patients with early-stage disease. With these new results, the Oncotype DX prostate cancer test becomes the first genomic test validated in all major short- and long-term end points, including adverse pathology, biochemical recurrence, metastasis and prostate cancer specific death.
- Reviews in Urology published a comprehensive economic analysis demonstrating use of Oncotype DX in low-risk prostate cancer patients leads to an increase in a net uptake of active surveillance and a net savings of $2,286 per patient - including the cost of the test - by decreasing unnecessary immediate invasive treatment.
- Presented results from eight Oncotype DX Breast Recurrence Score presentations at the European Society for Medical Oncology (ESMO) 2016 Congress, highlighting superior clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. To date, the unique clinical utility of Oncotype DX has been demonstrated with prospective outcomes results in over 63,000 breast cancer patients.
- Presented robust analytical validation study results on Oncotype SEQ Liquid Select at the ESMO 2016 Congress. The results demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible.
- Received acceptance to present six studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in December.

Corporate Leadership

- Announced participation in the Cancer Moonshot initiative, championed by Vice President Biden and the White House, by contributing data from the Company's liquid biopsy analytical validation study and experience building utility evidence for molecular diagnostics to help drive success for the Blood Tumor ATLAS.

This fact sheet contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the regulation of our tests; the applicability of clinical study results to actual outcomes; our ability to independently develop and commercialize and collaborate with companies to commercialize new tests and expand into new markets domestically and internationally; the risk that we may not obtain or maintain sufficient levels of reimbursement, domestically or abroad; competition; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; and the other risks and uncertainties set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.